Advanced search
1 file | 1.01 MB Add to list

Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia : on the need for a screening strategy in clinical practice : a report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology

Author
Organization
Abstract
Background: Dysglycaemia defined as type 2 diabetes (T2DM) and impaired glucose tolerance (IGT), increases the risk of cardiovascular disease (CVD). The negative impact is more apparent in the presence of hypertension and/or dyslipidaemia. Thus, it seems reasonable to screen for dysglycaemia in patients treated for hypertension and/or dyslipidaemia. A simple screening algorithm would enhance the adoption of such strategy in clinical practice. Objectives: To test the hypotheses (1) that dysglycaemia is common in patients with hypertension and/or dyslipidaemia and (2) that initial screening with the Finnish Diabetes Risk Score (FINDRISC) will decrease the need for laboratory based tests. Methods: 2395 patients (age 18-80 years) without (i) a history of CVD or TDM2, (ii) prescribed blood pressure and/or lipid lowering drugs answered the FINDRISC questionnaire and had an oral glucose tolerance test (OGTT) and HbA1c measured. Results: According to the OGTT 934 (39%) had previously undetected dysglycaemia (T2DM 19%, IGT 20%). Of patients, who according to FINDRISC had a low, moderate or slightly elevated risk 20, 34 and 41% and of those in the high and very high-risk category 49 and 71% had IGT or T2DM respectively. The OGTT identified 92% of patients with T2DM, FPG + HbA1c 90%, FPG 80%, 2hPG 29% and HbA1c 22%. Conclusions: (1) The prevalence of dysglycaemia was high in patients treated for hypertension and/or dyslipidaemia. (2) Due to the high proportion of dysglycaemia in patients with low to moderate FINDRISC risk scores its initial use did not decrease the need for subsequent glucose tests. (3) FPG was the best test for detecting T2DM. Its isolated use is limited by the inability to disclose IGT. A pragmatic strategy, decreasing the demand for an OGTT, would be to screen all patients with FPG followed by OGTT in patients with IFG.
Keywords
Type 2 diabetes, Impaired glucose tolerance, Screening, FINDRISC, Dyslipidaemia, Hypertension, Primary care, IMPAIRED GLUCOSE-TOLERANCE, DENSITY-LIPOPROTEIN CHOLESTEROL, FINNISH DIABETES PREVENTION, CARDIOVASCULAR RISK-FACTORS, ACUTE MYOCARDIAL-INFARCTION, CORONARY-ARTERY-DISEASE, LIFE-STYLE INTERVENTION, TERM-FOLLOW-UP, INSULIN-RESISTANCE, FASTING GLUCOSE

Downloads

  • 12933 2018 Article 665.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 1.01 MB

Citation

Please use this url to cite or link to this publication:

MLA
Shahim, Bahira, Viveca Gyberg, Dirk De Bacquer, et al. “Undetected Dysglycaemia Common in Primary Care Patients Treated for Hypertension And/or Dyslipidaemia : on the Need for a Screening Strategy in Clinical Practice : a Report from EUROASPIRE IV a Registry from the EuroObservational Research Programme of the European Society of Cardiology.” CARDIOVASCULAR DIABETOLOGY 17 (2018): n. pag. Print.
APA
Shahim, B., Gyberg, V., De Bacquer, D., Kotseva, K., De Backer, G., Schnell, O., Tuomilehto, J., et al. (2018). Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia : on the need for a screening strategy in clinical practice : a report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology. CARDIOVASCULAR DIABETOLOGY, 17.
Chicago author-date
Shahim, Bahira, Viveca Gyberg, Dirk De Bacquer, Kornelia Kotseva, Gui De Backer, Oliver Schnell, Jaakko Tuomilehto, David Wood, and Lars Rydén. 2018. “Undetected Dysglycaemia Common in Primary Care Patients Treated for Hypertension And/or Dyslipidaemia : on the Need for a Screening Strategy in Clinical Practice : a Report from EUROASPIRE IV a Registry from the EuroObservational Research Programme of the European Society of Cardiology.” Cardiovascular Diabetology 17.
Chicago author-date (all authors)
Shahim, Bahira, Viveca Gyberg, Dirk De Bacquer, Kornelia Kotseva, Gui De Backer, Oliver Schnell, Jaakko Tuomilehto, David Wood, and Lars Rydén. 2018. “Undetected Dysglycaemia Common in Primary Care Patients Treated for Hypertension And/or Dyslipidaemia : on the Need for a Screening Strategy in Clinical Practice : a Report from EUROASPIRE IV a Registry from the EuroObservational Research Programme of the European Society of Cardiology.” Cardiovascular Diabetology 17.
Vancouver
1.
Shahim B, Gyberg V, De Bacquer D, Kotseva K, De Backer G, Schnell O, et al. Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia : on the need for a screening strategy in clinical practice : a report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology. CARDIOVASCULAR DIABETOLOGY. 2018;17.
IEEE
[1]
B. Shahim et al., “Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia : on the need for a screening strategy in clinical practice : a report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology,” CARDIOVASCULAR DIABETOLOGY, vol. 17, 2018.
@article{8554281,
  abstract     = {Background: Dysglycaemia defined as type 2 diabetes (T2DM) and impaired glucose tolerance (IGT), increases the risk of cardiovascular disease (CVD). The negative impact is more apparent in the presence of hypertension and/or dyslipidaemia. Thus, it seems reasonable to screen for dysglycaemia in patients treated for hypertension and/or dyslipidaemia. A simple screening algorithm would enhance the adoption of such strategy in clinical practice. 
Objectives: To test the hypotheses (1) that dysglycaemia is common in patients with hypertension and/or dyslipidaemia and (2) that initial screening with the Finnish Diabetes Risk Score (FINDRISC) will decrease the need for laboratory based tests. 
Methods: 2395 patients (age 18-80 years) without (i) a history of CVD or TDM2, (ii) prescribed blood pressure and/or lipid lowering drugs answered the FINDRISC questionnaire and had an oral glucose tolerance test (OGTT) and HbA1c measured. 
Results: According to the OGTT 934 (39%) had previously undetected dysglycaemia (T2DM 19%, IGT 20%). Of patients, who according to FINDRISC had a low, moderate or slightly elevated risk 20, 34 and 41% and of those in the high and very high-risk category 49 and 71% had IGT or T2DM respectively. The OGTT identified 92% of patients with T2DM, FPG + HbA1c 90%, FPG 80%, 2hPG 29% and HbA1c 22%. 
Conclusions: (1) The prevalence of dysglycaemia was high in patients treated for hypertension and/or dyslipidaemia. (2) Due to the high proportion of dysglycaemia in patients with low to moderate FINDRISC risk scores its initial use did not decrease the need for subsequent glucose tests. (3) FPG was the best test for detecting T2DM. Its isolated use is limited by the inability to disclose IGT. A pragmatic strategy, decreasing the demand for an OGTT, would be to screen all patients with FPG followed by OGTT in patients with IFG.},
  articleno    = {21},
  author       = {Shahim, Bahira and Gyberg, Viveca and De Bacquer, Dirk and Kotseva, Kornelia and De Backer, Gui and Schnell, Oliver and Tuomilehto, Jaakko and Wood, David and Rydén, Lars},
  issn         = {1475-2840},
  journal      = {CARDIOVASCULAR DIABETOLOGY},
  keywords     = {Type 2 diabetes,Impaired glucose tolerance,Screening,FINDRISC,Dyslipidaemia,Hypertension,Primary care,IMPAIRED GLUCOSE-TOLERANCE,DENSITY-LIPOPROTEIN CHOLESTEROL,FINNISH DIABETES PREVENTION,CARDIOVASCULAR RISK-FACTORS,ACUTE MYOCARDIAL-INFARCTION,CORONARY-ARTERY-DISEASE,LIFE-STYLE INTERVENTION,TERM-FOLLOW-UP,INSULIN-RESISTANCE,FASTING GLUCOSE},
  language     = {eng},
  pages        = {11},
  title        = {Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia : on the need for a screening strategy in clinical practice : a report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology},
  url          = {http://dx.doi.org/10.1186/s12933-018-0665-4},
  volume       = {17},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: